Journal of Clinical Endocrinology & Metabolism, Vol 76, 1217-1223, Copyright © 1993 by Endocrine Society

ARTICLES

An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial

BR Carr, PB Marshburn, PT Weatherall, KD Bradshaw, NA Breslau, W Byrd, M Roark and MP Steinkampf
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas 75235-9032.

The purpose of this study was to prospectively compare the effectiveness of administering medroxyprogesterone acetate (MPA; 20 mg/day) in either the first (protocol A) or last (protocol B) 12-week period along with a 6-month course of the GnRH analog (GnRH-a; leuprolide acetate; 1 mg/day, sc) on uterine and leiomyomata volumes and hormone (estradiol, LH, and FSH) and serum lipid (total cholesterol, triglycerides, and high and low density lipoprotein) levels. Sixteen women were randomized into protocol A or B, received either MPA or placebo along with GnRH-a, respectively, and were then crossed over at 12 weeks to placebo or MPA, respectively, for the final 12-week interval of GnRH-a therapy. Total, myoma, and nonmyoma uterine volumes were determined by magnetic resonance imaging, and serum studies were performed at the beginning of the study and at 12 and 24 weeks. In both protocols, LH and estradiol levels declined by 80-90% (P < 0.03) and 55-72% (P < 0.02) of the baseline, respectively, at 12 weeks and remained at this level at 24 weeks. There were no significant changes in the other laboratory tests between protocols or longitudinally over time. Total uterine volume decreased to 73% of the baseline at 12 weeks in protocol B (P < 0.04), but did not change in protocol A. After crossover at 12 weeks, the total uterine volume of women in protocol A decreased to 74% of the baseline (P < 0.02) at 24 weeks. Between-protocol comparisons demonstrated a greater decline in total uterine volume in protocol B than A at 12 weeks, but after cross- over, MPA addition was associated with a significant increase in total uterine volume (protocol B) compared to a decrease in protocol A at 24 weeks (P < 0.005). In contrast, although myoma volume declined in both protocols, no significant changes in myoma volume were detected within or between groups over the treatment period. Nonmyoma volume changes in protocols A and B roughly paralleled total uterine volume changes, with MPA coadministration showing a correlation with a reversal in the GnRH- a-associated decrease in nonmyomatous tissue volume.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				X. Luo, P. Yin, S. Reierstad, H. Ishikawa, Z. Lin, M. E. Pavone, H. Zhao, E. E. Marsh, and S. E. Bulun Progesterone and Mifepristone Regulate L-Type Amino Acid Transporter 2 and 4F2 Heavy Chain Expression in Uterine Leiomyoma Cells J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4533 - 4539. [Abstract] [Full Text] [PDF]

				A. V. Hoekstra, E. C. Sefton, E. Berry, Z. Lu, J. Hardt, E. Marsh, P. Yin, J. Clardy, D. Chakravarti, S. Bulun, et al. Progestins Activate the AKT Pathway in Leiomyoma Cells and Promote Survival J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1768 - 1774. [Abstract] [Full Text] [PDF]

				J. Wilkens, K. Chwalisz, C. Han, J. Walker, I. T. Cameron, S. Ingamells, A. C. Lawrence, M. A. Lumsden, D. Hapangama, A. R. W. Williams, et al. Effects of the Selective Progesterone Receptor Modulator Asoprisnil on Uterine Artery Blood Flow, Ovarian Activity, and Clinical Symptoms in Patients with Uterine Leiomyomata Scheduled for Hysterectomy J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4664 - 4671. [Abstract] [Full Text] [PDF]

				W. Chen, N. Ohara, J. Wang, Q. Xu, J. Liu, A. Morikawa, H. Sasaki, S. Yoshida, D. A. Demanno, K. Chwalisz, et al. A Novel Selective Progesterone Receptor Modulator Asoprisnil (J867) Inhibits Proliferation and Induces Apoptosis in Cultured Human Uterine Leiomyoma Cells in the Absence of Comparable Effects on Myometrial Cells J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1296 - 1304. [Abstract] [Full Text] [PDF]

				K. Chwalisz, M. C. Perez, D. DeManno, C. Winkel, G. Schubert, and W. Elger Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis Endocr. Rev., May 1, 2005; 26(3): 423 - 438. [Abstract] [Full Text] [PDF]

				X. Luo, L. Ding, J. Xu, R. S. Williams, and N. Chegini Leiomyoma and Myometrial Gene Expression Profiles and Their Responses to Gonadotropin-Releasing Hormone Analog Therapy Endocrinology, March 1, 2005; 146(3): 1074 - 1096. [Abstract] [Full Text] [PDF]

				S. Palomba, F. Orio Jr, T. Russo, A. Falbo, T. Cascella, P. Doldo, C. Nappi, G. Lombardi, P. Mastrantonio, and F. Zullo Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas Hum. Reprod., June 1, 2004; 19(6): 1308 - 1314. [Abstract] [Full Text] [PDF]

				T. Maruo, N. Ohara, J. Wang, and H. Matsuo Sex steroidal regulation of uterine leiomyoma growth and apoptosis Hum. Reprod. Update, May 1, 2004; 10(3): 207 - 220. [Abstract] [Full Text] [PDF]

				N. Chegini, J. Verala, X. Luo, J. Xu, and R. S. Williams Gene Expression Profile of Leiomyoma and Myometrium and the Effect of Gonadotropin Releasing Hormone Analogue Therapy Reproductive Sciences, April 1, 2003; 10(3): 161 - 171. [Abstract] [PDF]

				S. Palomba, T. Russo, F. Orio Jr, L. Tauchmanova, E. Zupi, P. L. B. Panici, C. Nappi, A. Colao, G. Lombardi, and F. Zullo Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial Hum. Reprod., December 1, 2002; 17(12): 3213 - 3219. [Abstract] [Full Text] [PDF]

				S. Palomba, F. Orio Jr., M. Morelli, T. Russo, M. Pellicano, C. Nappi, P. Mastrantonio, G. Lombardi, A. Colao, and F. Zullo Raloxifene Administration in Women Treated with Gonadotropin-Releasing Hormone Agonist for Uterine Leiomyomas: Effects on Bone Metabolism J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4476 - 4481. [Abstract] [Full Text] [PDF]

				S. Palomba, F. Orio Jr., M. Morelli, T. Russo, M. Pellicano, E. Zupi, G. Lombardi, C. Nappi, P. L. B. Panici, and F. Zullo Raloxifene Administration in Premenopausal Women with Uterine Leiomyomas: A Pilot Study J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3603 - 3608. [Abstract] [Full Text] [PDF]

				H. Sumitani, M. Shozu, T. Segawa, K. Murakami, H.-J. Yang, K. Shimada, and M. Inoue In Situ Estrogen Synthesized by Aromatase P450 in Uterine Leiomyoma Cells Promotes Cell Growth Probably Via an Autocrine/Intracrine Mechanism Endocrinology, October 1, 2000; 141(10): 3852 - 3861. [Abstract] [Full Text] [PDF]

				C. L. Walker, K. D. Burroughs, B. Davis, K. Sowell, J. I. Everitt, and R. Fuchs-Young Preclinical Evidence for Therapeutic Efficacy of Selective Estrogen receptor Modulators for Uterine Leiomyoma Reproductive Sciences, July 1, 2000; 7(4): 249 - 256. [Abstract] [PDF]

				N. Chegini, X.-M. Tang, and C. Ma Regulation of Transforming Growth Factor-{beta}1 Expression by Granulocyte Macrophage-Colony-Stimulating Factor in Leiomyoma and Myometrial Smooth Muscle Cells J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4138 - 4143. [Abstract] [Full Text]

				E. A. Stewart, A. R. Rhoades, and R. A. Nowak Leuprolide Acetate-Treated Leiomyomas Retain Their Relative Overexpression of Collagen Type I and Collagen Type III Messenger Ribonucleic Acid Reproductive Sciences, January 1, 1998; 5(1): 44 - 47. [Abstract] [PDF]

				J. Andersen and R. L. Barbieri Abnormal Gene Expression in Uterine Leiomyomas Reproductive Sciences, September 1, 1995; 2(5): 663 - 672. [Abstract] [PDF]

				E. J. Quilligan Obstetrics and Gynecology JAMA, June 7, 1995; 273(21): 1700 - 1702. [Abstract] [PDF]